SCHEMBL4075633

SCHEMBL4075633

CCOC(OCC)C(C#N)C=O

nearest known ligand 0.31

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4830005 0.98
Potassium SCHEMBL29519191 0.98
SCHEMBL18775436 0.81 LMNA (0.33)
SCHEMBL15910483 0.75
SCHEMBL4485232 0.73
SCHEMBL10445030 0.73
SCHEMBL10806666 0.69 THRB (0.38) THRB
SCHEMBL21790201 0.69 THRB (0.38) THRB
SCHEMBL8041239 0.68 LMNA (0.50)
SCHEMBL8040302 0.67 LMNA (0.41) THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10954194-B2 18-20 member bi-polycyclic compounds Haro Pharmaceuticals Inc. (US) 2021-03-23 US disclosed
US-10752591-B2 18-20 member bi-polycyclic compounds Haro Pharmaceuticals Inc. (US) 2020-08-25 US disclosed
US-10377715-B2 18-20 member bi-polycyclic compounds Haro Pharmaceuticals Inc. (US) 2019-08-13 US disclosed
US-20170114019-A1 18-20 MEMBER BI-POLYCYCLIC COMPOUNDS HARO PHARMACEUTICAL INC. 2017-04-27 US disclosed
WO-2015188015-A1 18-20 MEMBER BI-POLYCYCLIC COMPOUNDS HARO PHARMACEUTICAL INC. (US) 2015-12-10 WO disclosed
US-20090306380-A1 Process for preparing 4-amino-2-alkylthio-5-pyrimidinecarbaldehyde UBE INDUSTRIES, LTD. (JP) 2009-12-10 US disclosed
CN-100432073-C 6-alkoxy-pyrido-pyrimidines as p-38 MAP kinase inhibitors HOFFMANN LA ROCHE (CH) 2008-11-12 CN disclosed
CN-100376571-C 6-substituted pyrido-pyrimidines HOFFMANN LA ROCHE (CH) 2008-03-26 CN disclosed
CN-1675207-A 6-alkoxy-pyrido-pyrimidines as p-38 MAP kinase inhibitors HOFFMANN LA ROCHE (CH) 2005-09-28 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306380-A1 Process for preparing 4-amino-2-alkylthio-5-pyrimidinecarbaldehyde NUDT1, DPYD, TPMT THRB 2769/4885
US-10752591-B2 18-20 member bi-polycyclic compounds TNNI3, TNNC1, MYLK2 THRB 1612/4885
US-10377715-B2 18-20 member bi-polycyclic compounds CKMT1A; CKMT1B, MYLK2, CPT1B THRB 3024/4885
US-10954194-B2 18-20 member bi-polycyclic compounds BRCA1, UGT2B17, TP53 THRB 3131/4885
US-20170114019-A1 18-20 MEMBER BI-POLYCYCLIC COMPOUNDS CKMT1A; CKMT1B, MYLK2, CPT1B THRB 3024/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.